Table 3

Hazard Ratios (HRs) and 95% confidence intervals (CIs) of hepatocellular carcinoma (HCC) according to hepatitis B and C virus infection status
Infection status No. of subjects Person-years No. of HCC HRa(95% CI)
HBsAg(−) / anti-HCV(−) 5744 53,504 16 1.0 (reference)
HBsAg(+) / anti-HCV(−) 335 2,981 15 17.1 (8.4-34.8)
HBsAg(−) / anti-HCV(+) 360 3,731 12 10.4 (4.9-22.1)
HBsAg(+) / anti-HCV(+) 14 133 3 115.0 (32.5-407.3)
SI and 95% CI: 4.5 (1.3-15.5)b

HBsAg, hepatitis B surface antigen; anti-HCV, antibodies against hepatitis C virus. aHR: age- and sex-adjusted. bSI: synergy index=(RR11-1)/(RR01+RR10-2), in which RR11=relative risk of the joint effect of two risk factors; RR01 and RR10=relative risk of each risk factor in the absence of the other. Two hundred and forty-one subjects including 4 HCC cases had no information on HBsAg or anti-HCV, and were excluded from the analysis.

Oh et al.

Oh et al. BMC Cancer 2012 12:452   doi:10.1186/1471-2407-12-452

Open Data